|
|
Article: Antisoma's Stock Falls On Phase III Miss With R1549.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
LONDON - Antisoma plc's share price was halved Monday after the company announced its lead product, R1549, failed in a Phase III ovarian cancer trial - survival of R1549-treated patients was no better than patients in the comparative arm.
Glyn Edwards, CEO, told BioWorld Today: "Obviously we are very disappointed and disappointed for cancer patients as well. But that's the way this business goes. There was no significant difference in survival and no trends that we would consider [significant enough] to take the product forward."
R1549 is partnered to F. Hoffmann-La Roche Ltd., of Basel, Switzerland, and ...